JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, today announced that it has signed a worldwide exclusive license agreement with Yeda Research and Development Company Ltd., the technology transfer company of the Weizmann Institute of Science, for the development and commercialization of BL-4050, a novel peptide for the treatment of cancer. Financial terms of the license were not disclosed.
